Kuros Biosciences

Switzerland
Schlieren, Zurich, Switzerland, 8952

Company profile

Kuros Biosciences company profile

Cytos is a public biopharmaceutical company focused on the development of targeted immunotherapies with a VLP B-cell vaccines platform and ongoing preclinical development programs based on the platform.

Business identity

Contact email
[email protected]
Phone number
4117334644
Operating status
Active
Company type
For Profit
Employee range
51-100 employees
Revenue range
$0+
Founded
1995-01-01, Year

Headquarters

Postal code
8952
Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
5
Total equity funding
$125.6M
Last funding
Post IPO Equity / $40M / 2012-03-21
Last equity funding
Post IPO Equity / $40M
Investors
11
Founders
1
Articles
29
Exited on
2002-10-02

Founders and investors

Founders

Wolfgang A. Renner

Investors

AbingworthAisling CapitalAlta PartnersNovartisvenBio Partners